Contact Us | Therakos

Our multi-lingual Customer Service Team are available as follows:

Customer Service Team from 9am to 6pm, Monday to Friday (GMT+1)

Technical and Clinical Service Team from 8am to 5pm, Monday to Friday (GMT+1)

Technical and Clinical Support

For enquiries relating to technical and clinical support please contact the hotline at:

INTERNATIONAL TOLL-FREE: 00800 84372567 (Accessible from most countries in Europe and The Middle East)

Support in English

+44 154 860 0009

0808 238 6011
(Toll-Free within the UK)
+44 208 338 0479
ecphelp@therakos.com
(For enquiries only)

Unterstützung auf Deutsch

+49 32 221 093 619

0800 181 1715
(Gebührenfreie Telefonnummer von Deutschland aus)
+49 61 097 009 318
ecphelp@therakos.com
(Nur für Informationsanfragen)

Support en Français

+33 18 288 0867
ecphelp@therakos.com
(Pour demande seulement)

Supporto in Italiano

+39 05 1042 0666

800 149 844
(Numero verde gratuito dall’Italia)
ecphelp@therakos.com
(Solo per richiesta di informazioni)

Asistencia en Español

+34 932 20 2094

800 600 798
ecphelp@therakos.com

(Solo para consultas)

Product Orders, Deliveries & Invoicing

For enquiries relating to product orders, deliveries or invoicing please contact us at:

Support in English

+44 1784 614060

0800 0698136
(Toll-Free within the UK)
+44 203 7441022
customerservice.emea.en@mnk.com

Unterstützung auf Deutsch

+49 6996759138

0800 723 9486
(Gebührenfreie Telefonnummer von Deutschland aus)
+49 69 5060 6793
+49 69 5060 6794
customerservice.emea.de@mnk.com

Support en Français

+33 18 626 0833

080 508 2214
(Appel gratuit depuis la France)
+33 18 020 6913
customerservice.emea.fr@mnk.com

Supporto in Italiano

+39 06 9480 0373

800 684 170
(Numero verde gratuito dall’Italia)
+39 06 9318 8019
customerservice.emea.it@mnk.com

Asistencia en Español

+34 914 141 703
customerservice.emea.es@mnk.com

For billing enquiries please contact CritCareTKS-accountsreceivableEU@mnk.com

Adverse Events

To report an adverse event please contact us at:

INTERNATIONAL FREEPHONE: 00800 84372567 (Available from most countries in Europe and Middle East and Africa)

Support in English

+44 154 860 0009

Within the UK:
0808 238 6011

Unterstützung auf Deutsch

+49 32 221 093 619

Innerhalb Deutschland:
0800 1811715

Support en Français

+33 18 288 0867

Supporto in Italiano

+39 051 042 0666

All’interno dell’Italia:
800 149 844

Asistencia en Español

+34 932 20 2094

Dentro de España:
800 600 798

Or contact us at ecphelp@therakos.com

Medical Information Request

For medical enquiries relating to Mallinckrodt products please contact us at medinfo@mnk.com

General
Enquiries

You can get in touch with us by using the form or calling us at:

+44 1784 614060

This request form is provided for your convenience to submit an enquiry directly to Therakos. This form is not intended to be used to report a product complaint, adverse event or to request immediate assistance with a patient treatment. No patient identifiable information should ever be included in this form.

Name

*Email

Phone:

Country:

*Message:

If you would like to learn more about how we collect and manage your data please refer to our privacy policy

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS™ CELLEX™ Photopheresis System is indicated for patients older than 18 years of age for the administration of photopheresis in the following:

Cutaneous T Cell Lymphoma (CTCL)
Solid Organ Transplant Rejection (SOT) (heart, lung)

The THERAKOS™ CELLEX™ Photopheresis System is indicated in patients older than 3 years of age for the management of:

Acute and Chronic Graft versus Host Disease (aGvHD, cGvHD)

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³
Patients who have coagulation disorders or who have previously had a splenectomy

Warnings and Precautions

THERAKOS^TMPhotopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Consult the 8-methoxypsoralen (Methoxsalen (20 micrograms / mL)) professional leaflet or the oral 8-methoxypsoralen formulation package insert before prescribing or dispensing any medication.

Warnings and Precautions

Patients exhibiting multiple basal cell carcinomas or having a history of basal cell carcinoma should be diligently observed and treated.
Methoxsalen may cause fetal harm when given to a pregnant woman. Women undergoing photopheresis should be advised to avoid becoming pregnant.
Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

Our multi-lingual Customer Service Team are available as follows:

Technical and Clinical Support

Support in English

Unterstützung auf Deutsch

Support en Français

Supporto in Italiano

Asistencia en Español

Product Orders, Deliveries & Invoicing

Support in English

Unterstützung auf Deutsch

Support en Français

Supporto in Italiano

Asistencia en Español

Adverse Events

Support in English

Unterstützung auf Deutsch

Support en Français

Supporto in Italiano

Asistencia en Español

Medical Information Request

GeneralEnquiries

Welcome to the Home of ECP

You are leaving the Therakos.eu website.

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOSTM PHOTOPHERESIS

General
Enquiries

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS